Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NextCure, Inc. - Common Stock (NQ:NXTC)

12.74 -0.67 (-5.00%)
Streaming Delayed Price Updated: 3:06 PM EST, Dec 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NextCure, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
From NextCure
Via GlobeNewswire
News headline image
NextCure Announces Acceptance of IND Application for LNCB74
LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem Biosciences 
From NextCure
Via GlobeNewswire
News headline image
NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
NXTC Stock Earnings: NextCure Beats EPS for Q4 2023 ↗
NXTC stock results show that NextCure beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta
From NextCure
Via GlobeNewswire
News headline image
NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting
From NextCure
Via GlobeNewswire
News headline image
NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024
From NextCure
Via GlobeNewswire
News headline image
NXTC Stock Earnings: NextCure Misses EPS for Q2 2024 ↗
NXTC stock results show that NextCure missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
From NextCure
Via GlobeNewswire
News headline image
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
From NextCure
Via GlobeNewswire
News headline image
NXTC Stock Earnings: NextCure Misses EPS for Q1 2024 ↗
NXTC stock results show that NextCure missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
NextCure Provides Business Update and Reports First Quarter 2024 Financial Results
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024
From NextCure
Via GlobeNewswire
News headline image
NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74 
From NextCure
Via GlobeNewswire
News headline image
NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
From NextCure
Via GlobeNewswire
News headline image
NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
From NextCure
Via GlobeNewswire
News headline image
Wall Street’s Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich ↗
The market is surging higher after dovish Fed comments. Here are seven of Wall Street’s favorite penny stocks that can help make you rich 
Via InvestorPlace
Topics Economy
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
NextCure Provides Business Update and Reports Full Year 2023 Financial Results
From NextCure
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
From NextCure
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
From NextCure
Via GlobeNewswire
News headline image
NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
From NextCure
Via GlobeNewswire
News headline image
Why Amtech Systems Shares Are Trading Higher By Over 30%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.